Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 4 , Pages 346-352 , July 2008

The once and future role of cytoreductive nephrectomy

Received 13 April 2007 ,Accepted 25 May 2007.

References 

  1. Janzen NK, Kim HL, Figlin RA, et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin N Am. 2003;30:843–852
  2. Medical Research Council Collaborators. Interferon-α and survival in metastatic renal cell carcinoma: Early results of a randomized controlled trial. Lancet. 1999;353:14–17
  3. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib vs. interferon α in metastatic renal cell carcinoma. N Engl J Med. 2007;356:115–124
  4. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear cell renal cell carcinoma. N Engl J Med. 2007;356:125–134
  5. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: The role of interleukin-2. Cancer. 1997;80:1198–1220
  6. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously-treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454–463
  7. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002;20:4559–4566
  8. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon-α 2b compared with interferon-α 2b alone for metastatic renal cell carcinoma. N Engl J Med. 2001;345:1655–1659
  9. Mickisch GH, Garin A, Van Poppel H, et al. Radical nephrectomy plus interferon-α based immunotherapy compared with interferon-α alone in metastatic renal cell carcinoma: A randomized trial. Lancet. 2001;358:966–970
  10. Bromwich E, Hendry D, Aitchison M. Cytoreductive nephrectomy: Is it a realistic option in patients with renal cancer?. BJU Int. 2002;89:523–525
  11. Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis. J Urol. 2004;171:1071–1076
  12. Mosharafa A, Koch M, Shalhav A, et al. Nephrectomy for metastatic renal cell carcinoma: Indiana University experience. Urology. 2003;62:636–640
  13. Walther MM, Patel B, Choyke PL, et al. Hypercalcemia in patients with metastatic renal cell carcinoma: Effect of nephrectomy and metabolic evaluation. J Urol. 1997;159:733–739
  14. Fujikawa K, Matsui Y, Miura K, et al. Serum immunosuppressive acidic protein and natural killer cell activity in patients with metastatic renal cell carcinoma before and after nephrectomy. J Urol. 2000;164:673–675
  15. Dadian G, Riches PG, Henderson DC, et al. Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy. Br J Urol. 1994;74:15–22
  16. Lokich J. Spontaneous regression of metastatic renal cancer: Case report and literature review. Am J Clin Oncol. 1997;20:416–418
  17. Montie JE, Stewart BH, Straffon RA. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol. 1977;117:272–275
  18. Rackley R, Novick A, Klein E, et al. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol. 1994;152:1399–1403
  19. Krishnamurthi V, Novick AC, Bukowski RM. Efficacy of multimodality therapy in advanced renal cell carcinoma. Urology. 1998;51:933–937
  20. Wagner JR, Walther MM, Linehan WM, et al. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol. 1999;162:43–45
  21. Bex A, Kerst M, Mallo H, et al. Interferon-α 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: A consecutive study. Eur Urol. 2006;49:76–81
  22. Halbert RJ, Figlin RA, Atkins MB, et al. Treatment of patients with metastatic renal cell carcinoma: A RAND Appropriateness Panel. Cancer. 2006;107:2375–2383
  23. Walther MM, Lyne C, Libutti SK, et al. Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: A pilot study. Urology. 1999;53:496–501
  24. Rabets JC, Kaouk J, Fergany A, et al. Laparoscopic vs. open cytoreductive nephrectomy for metastatic renal cell carcinoma. Urology. 2004;64:930–934
  25. Matin SF, Madsen LT, Wood CG. Laparoscopic cytoreductive nephrectomy: The M. D. Anderson Cancer Center Experience. Urology. 2006;68:528–532
  26. Cohen HT, McGovern FJ. Renal cell carcinoma. N Engl J Med. 2005;353:2477–2490
  27. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with Bevacizumab. J Surg Oncol. 2005;91:173–180
  28. Bennett RT, Lerner SE, Taub HC, et al. Cytoreductive surgery for Stage IV renal cell carcinoma. J Urol. 1995;154:32–34
  29. Franklin JR, Figlin R, Rauch J, et al. Cytoreductive surgery in the management of metastatic renal cell carcinoma: The UCLA experience. Semin Urol Oncol. 1996;14:230–236
  30. Walther MM, Yang JC, Pass HI, et al. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol. 1997;158:1675–1678
  31. Fallick ML, McDermott DF, LaRock D, et al. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol. 1997;158:1691–1695
  32. Wood CG, Huber N, Madsen L, et al. Clinical variables that predict survival cytoreductive nephrectomy for metastatic renal cell carcinoma. J Urol. 2001;165:184A

PII: S1078-1439(07)00161-5

doi: 10.1016/j.urolonc.2007.05.029

Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 4 , Pages 346-352 , July 2008

Article Tools